knopp

  1. T

    Biogen Idec And Knopp Neurosciences Announce License Agreement For Late-Stage ALS Dru

    Biogen Idec (NASDAQ: BIIB) and Knopp Neurosciences announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's...
  2. T

    Knopp Neurosciences Presents Further Encouraging Trends In Its Phase 2 Study Of KNS-7

    In an invited presentation today before the annual meeting of the American Academy of Neurology, Knopp Neurosciences Inc. ("Knopp") described further encouraging trends observed in a previously reported Phase 2 study of KNS-760704 (dexpramipexole) in ALS. Knopp reported that post hoc analyses...
Back
Top